Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00550784

NCT00550784
Completed Phase 1

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with ovarian cancer, cancer of the lining of the abdomen (peritoneal cancer), or fallopian tube cancer, confirmed by a tissue test (biopsy)
  • Your cancer is at an advanced stage (Stage III or IV) and you were treated with a standard chemotherapy regimen containing platinum, with less than 2 cm of cancer remaining and no signs of the cancer growing after that treatment
  • If your cancer originally started at Stage IV, you showed a clear response (either complete or partial) to your initial treatment
  • Alternatively, your cancer came back and your CA-125 blood marker level (a cancer indicator) dropped by at least half and stayed that way for 4 weeks after your most recent chemotherapy
  • Or, your cancer came back and you responded well (completely or partially) to further chemotherapy given for the relapse
  • If your cancer can be measured or detected on scans, it must have partially responded to previous treatment
  • You are generally able to carry out normal daily activities (as measured by a standard health scale scoring 70–100%)
  • Your blood counts, liver, and kidney function are within acceptable levels (confirm with trial site)
  • Your heart pumping function is normal at rest, confirmed by a special scan
  • Your lung function meets the required breathing capacity levels
  • It has been at least 4 weeks since your last chemotherapy or radiotherapy
  • You test negative for Hepatitis B, Hepatitis C, and HIV

Who may not be able to join:

  • You have a noticeable build-up of fluid around your lungs
  • You have an active heart condition that the doctor believes would make chemotherapy unsafe for you
  • You have a history of serious psychiatric conditions that could be significantly affected by treatment
  • You have significant nerve damage or numbness in your hands or feet
  • You have previously had radiotherapy covering your whole abdomen
  • You test positive for Hepatitis B, Hepatitis C, or HIV

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 1
Sponsor
City of Hope Medical Center
Registry
clinicaltrials_gov
Start date
1 January 2001
Est. completion
1 October 2014

Primary endpoints

Toxicity; Tumor response; Reason patient is removed from study; Disease progression; Overall survival; Progression-free survival; Time to progression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov